LLY
Eli Lilly and Company
NYQ
$1,064.15
-18.05
(-1.67%)
Extended · +1.02σ
Grade C
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$948.9B
P/E ttm
37.7
Fwd P/E
23.9
Beta
0.48
Day range
$1064.15
52w range
$850.51 – $1149.10
Avg vol
3.1M
RSI(2)
17.2
ROE
107.5%
Net mgn
35.0%
FCF mgn
12.7%
Debt/Eq
1.39
Div yld
65.00%
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earn
2026-08-05
Matrix setup grades
Long
—
score 9 · tech 9 / 80 · support 0 / 20
above KC1 lower, +0.96 ATR from EMA21 · no notable pattern
Short
C
score 26 · tech 26 / 80 · support 0 / 20
KC1 upper, +0.96 ATR from EMA21 · no notable pattern
- · KC1 upper stretch — light pop
- · RSI hook from overbought (59)
- · Aligned with weak downtrend
Options · swing
See more →
CALL
$1070
2026-07-02
$42.00
PUT
$930
2026-07-02
$4.15
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- 8.55 / 6.79
- Surprise
- +25.9%
- Next report
- 2026-08-05
About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25,…